(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 11.07% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.56%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Neuropace's revenue in 2025 is $88,570,000.On average, 3 Wall Street analysts forecast NPCE's revenue for 2025 to be $3,177,147,068, with the lowest NPCE revenue forecast at $3,152,335,944, and the highest NPCE revenue forecast at $3,202,950,636. On average, 3 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,328,759,573, with the lowest NPCE revenue forecast at $3,283,338,677, and the highest NPCE revenue forecast at $3,357,441,232.
In 2027, NPCE is forecast to generate $4,174,719,640 in revenue, with the lowest revenue forecast at $4,023,371,787 and the highest revenue forecast at $4,326,067,493.